ATE427746T1 - 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren - Google Patents

5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren

Info

Publication number
ATE427746T1
ATE427746T1 AT00922625T AT00922625T ATE427746T1 AT E427746 T1 ATE427746 T1 AT E427746T1 AT 00922625 T AT00922625 T AT 00922625T AT 00922625 T AT00922625 T AT 00922625T AT E427746 T1 ATE427746 T1 AT E427746T1
Authority
AT
Austria
Prior art keywords
treatment
methylindirubine
human solid
solid tumors
human
Prior art date
Application number
AT00922625T
Other languages
English (en)
Inventor
Gerhard Eisenbrand
Heinz Herbert Fiebig
Weici Tang
Doris Marko
Ralph Hissel
Original Assignee
Heinz Herbert Fiebig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heinz Herbert Fiebig filed Critical Heinz Herbert Fiebig
Application granted granted Critical
Publication of ATE427746T1 publication Critical patent/ATE427746T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT00922625T 1999-04-12 2000-04-11 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren ATE427746T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99106206 1999-04-12
EP99107474 1999-04-29

Publications (1)

Publication Number Publication Date
ATE427746T1 true ATE427746T1 (de) 2009-04-15

Family

ID=26152939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922625T ATE427746T1 (de) 1999-04-12 2000-04-11 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren

Country Status (11)

Country Link
US (1) US6664285B1 (de)
EP (1) EP1218004B1 (de)
JP (1) JP2002541189A (de)
CN (1) CN1378447A (de)
AT (1) ATE427746T1 (de)
AU (1) AU775633B2 (de)
BR (1) BR0009771A (de)
CA (1) CA2369626C (de)
DE (1) DE60041974D1 (de)
MX (1) MXPA01010436A (de)
WO (1) WO2000061124A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
CA2469649C (en) * 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
EP1340745A1 (de) * 2002-02-20 2003-09-03 Gerhard Prof. Dr. Eisenbrand Indirubinderivate und deren Verwendung zur Behandlung von Krebs
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
FR2952819A1 (fr) * 2009-11-23 2011-05-27 Oreal Composition contenant au moins un precurseur de coloration derive d'oxindole et au moins un colorant indoline dione
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CN103274987A (zh) * 2013-06-07 2013-09-04 华东师范大学 3,3-二取代氧化吲哚衍生物及其合成方法和应用
CN103342674B (zh) * 2013-07-05 2015-08-19 华东师范大学 一类光学活性吡咯衍生物及其合成方法
KR101493324B1 (ko) 2013-07-11 2015-02-16 연세대학교 산학협력단 인디루빈 유도체를 포함하는 골길이 성장 촉진용 조성물
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
CN114533755B (zh) * 2022-03-23 2024-05-03 遵义医科大学 一种绞股蓝多糖与靛玉红在抗黑色素瘤药物上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609022B2 (ja) * 1981-06-19 1985-03-07 イスクラ産業株式会社 インジルビン誘導体およびそれを含有する抗腫瘍剤
JPS609023B2 (ja) * 1981-06-19 1985-03-07 イスクラ産業株式会社 インジルビン誘導体およびそれを含有する抗腫瘍剤
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
US5935581A (en) * 1996-07-24 1999-08-10 Kapadia; Govind J. Inhibitory effects of synthetic and natural colorants on carcinogenesis
CA2333661A1 (en) * 1998-05-29 1999-12-09 Cnrs (Centre National De Recherche Scientifique) France Innovation Scien Tifique Et Transfernt Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
CN1207924A (zh) * 1998-08-07 1999-02-17 刘克贤 治疗口腔、咽喉、食道疾病的药物及其制备方法
JP2002541244A (ja) * 1999-04-12 2002-12-03 ゲルハルト アイゼンブランド インジゴイドビスインドール誘導体

Also Published As

Publication number Publication date
JP2002541189A (ja) 2002-12-03
DE60041974D1 (de) 2009-05-20
US6664285B1 (en) 2003-12-16
WO2000061124A2 (en) 2000-10-19
AU4294900A (en) 2000-11-14
CA2369626C (en) 2009-01-13
EP1218004B1 (de) 2009-04-08
CA2369626A1 (en) 2000-10-19
EP1218004A2 (de) 2002-07-03
MXPA01010436A (es) 2002-09-18
CN1378447A (zh) 2002-11-06
WO2000061124A3 (en) 2002-05-02
AU775633B2 (en) 2004-08-05
BR0009771A (pt) 2002-01-08

Similar Documents

Publication Publication Date Title
ATE427746T1 (de) 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
DE60113733D1 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
DE60045508D1 (de) Dalda-analoge und ihre verwendung
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE69713300D1 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
NO20050640L (no) Rutenium anticancer komplekser
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
DE59508366D1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties